Navigation Links
Questcor Pharmaceuticals to Present at Investor Conferences in September
Date:9/5/2012

ANAHEIM, Calif., Sept. 5, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the following investor conferences in September 2012:

  • Morgan Stanley Global Healthcare Conference in New York City on September 11, 2012 at 3:30 PM ET.
  • G9: ThinkEquity's 9th Annual Growth Conference in New York City on September 12, 2012 at 3:30 PM ET.

A live webcast and subsequent archived replay of the presentations will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... 6 Roxane Laboratories, Inc. announced today the ... for Losartan Potassium Tablets USP, 25mg, 50mg and ... Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food ... immediate shipment to wholesalers and pharmacies nationwide. ...
... Texas, Oct. 6 DiFUSION Technologies Inc., a ... commercialization of its proprietary CleanFUZE™ anti-microbial technology for ... its new Xiphos™ line of posterior interbody devices ... spine, from L2 to SI, in skeletally mature ...
Cached Medicine Technology:Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... during and after being treated with post-surgical chemotherapy did not ... from it, according to researchers at Dana-Farber Cancer Institute. ... characterized as cancer in the large bowel area with ... the researchers found that while multivitamin use had no beneficial ...
... of smoking cessation treatments are currently available for the ... smoking each year, but success rates vary widely. Despite ... smoking cessation treatment are needed to help smokers pick ... A major new personalized medicine clinical trial, led by ...
... an intense network of collaborative research. Building on a tool ... recent issue of Brain , Dr. Yaniv Assaf of ... international team of scientists to understand how different parts of ... into a "brain atlas." Brain researchers already know that ...
... disease deaths and hospital admissions, particularly among people from ... Journal of Epidemiology and Community Health . Current ... has improved the overall quality of primary care in ... evidence to suggest that better quality primary care actually ...
... on conserving the use of antibacterial drugs, or face ... antibiotic-resistant infections, according to an analysis out today. ... being depleted by resistance, which occurs when infection-causing microbes ... to widely-used treatments. Most proposals to solve this problem ...
... of California, San Diego School of Medicine have shown ... examining dynamic geometric patterns than they do looking at ... either typical or developmentally delayed toddlers. The results ... patterns early in life may be a signature behavior ...
Cached Medicine News:Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Penn receives $12 million NIH grant to research personalized approach to smoking cessation 2Health News:Mapping a brain atlas 2Health News:Primary care financial incentives cut heart disease deaths and admissions 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Medicine Products: